911715-70-3

Upstream product

• 911715-69-0 (1R)-1-[3-(methylsulfonyl)phenyl]ethanol 

Downstream Products

• 911715-71-4 (2R)-2-{[2-amino-5-({(1R)-1-[3-(methylsulfonyl)phenyl]ethyl}thio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino}-4-methylpentan-1-ol 
• 911715-73-6 (2R)-2-{[2-methoxy-5-({(1R)-1-[3-(methylsulfonyl)phenyl]ethyl}thio)[1,3]-thiazolo[4,5-d]pyrimidin-7-yl]amino}-4-methylpentan-1-ol 
• 911715-72-5 (2R)-2-{[2-chloro-5-({(1R)-1-[3-(methylsulfonyl)phenyl]ethyl}thio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino}-4-methylpentan-1-ol 

Relevant academic research and scientific papers

NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES

There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.